GLP-1 Market
LLY $1170.14 ▲ +0.5% NVO $39.40 ▼ -1.0% PFE $27.93 ▲ +0.7% VKTX $40.85 ▲ +35.7% KLRA $12.79 ▲ +6.7% GPCR $36.91 ▲ +0.3% RHHBY $55.56 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Baricitinib

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
38 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

38 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for Baricitinib and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT01965132

    Korean College of Rheumatology Biologics and Targeted Therapy Registry

    Seoul National University Hospital 10000 participants Est. completion 2030-06-30 1 site
    Other conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
    View official trial listing →
  • Recruiting NCT NCT02714634

    Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

    Not yet reported University Hospital, Strasbourg, France 286 participants Est. completion 2029-03 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
    View official trial listing →
  • Recruiting NCT NCT02735707

    Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

    Not yet reported UMC Utrecht 20000 participants Est. completion 2028-02 408 sites
    Other conditions: Community-acquired Pneumonia, Influenza, COVID-19
    View official trial listing →
  • Recruiting NCT NCT03358693

    Molecular Signatures in Inflammatory Skin Disease

    Prof. Dr. Stephan Weidinger 300 participants Est. completion 2029-12-31 1 site
    Other conditions: Atopic Dermatitis, Psoriasis
    View official trial listing →
  • Recruiting NCT NCT03414502

    Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

    Not yet reported University of Nebraska 400 participants Est. completion 2029-03 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT03549416

    BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis

    UMC Utrecht 1200 participants Est. completion 2028-12-31 14 sites
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Recruiting NCT NCT03773965

    A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

    Not yet reported Eli Lilly and Company 190 participants Est. completion 2031-07 78 sites Stand-alone
    Other conditions: Juvenile Idiopathic Arthritis
    View official trial listing →
  • Recruiting NCT NCT04381936

    Randomised Evaluation of COVID-19 Therapy

    Not yet reported University of Oxford 70000 participants Est. completion 2038-09-30 16 sites
    Other conditions: Pneumonia
    View official trial listing →
  • Recruiting NCT NCT04692493

    RA-PRO PRAGMATIC TRIAL

    Not yet reported University of Alabama at Birmingham 924 participants Est. completion 2029-07-31 49 sites
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT04972760

    Baricitinib in Patients With Relapsing or naïve Dermatomyositis

    Not yet reported Assistance Publique - Hôpitaux de Paris 62 participants Est. completion 2028-02-28 1 site Stand-alone
    Other conditions: Dermatomyositis
    View official trial listing →
  • Recruiting NCT NCT05003310

    ConsideRAte Study - Splenic Stimulation for RA

    Not yet reported Galvani Bioelectronics 28 participants Est. completion 2032-04 14 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT05099315

    Microbiome in Atopic Dermatitis Under Systemic Therapy

    Charite University, Berlin, Germany 600 participants Est. completion 2025-12-31 1 site
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Recruiting NCT NCT05305066

    Stand UP to Rheumatoid Arthritis (SUPRA)

    Not yet reported Marie Hudson, MD 75 participants Est. completion 2030-12 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT05452564

    Baricitinib for Reduction of HIV - CNS

    Not yet reported William Tyor 95 participants Est. completion 2028-01 2 sites Stand-alone
    Other conditions: Human Immunodeficiency Virus
    View official trial listing →
  • Recruiting NCT NCT05674695

    Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

    Fundación Academia Española de Dermatología 2500 participants Est. completion 2029-01-01 9 sites
    Other conditions: Dermatitis, Atopic
    View official trial listing →
  • Recruiting NCT NCT05723198

    A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

    Not yet reported Eli Lilly and Company 595 participants Est. completion 2033-09 127 sites Stand-alone
    Other conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
    View official trial listing →
  • Recruiting NCT NCT05849038

    Inflammation and Depression in People With HIV

    Not yet reported Emory University 60 participants Est. completion 2027-11 2 sites Stand-alone
    Other conditions: HIV, Depression, Anhedonia
    View official trial listing →
  • Recruiting NCT NCT05955066

    Effect of JAK Inhibitor on Erosion Healing in RA

    Not yet reported Chinese University of Hong Kong 60 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT06065046

    Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

    Not yet reported Tang-Du Hospital 100 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Traumatic Brain Injury
    View official trial listing →
  • Recruiting NCT NCT06381661

    Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

    Not yet reported Assistance Publique - Hôpitaux de Paris 2000 participants Est. completion 2031-07-09 8 sites Stand-alone
    Other conditions: Sepsis
    View official trial listing →
  • Recruiting NCT NCT06490757

    A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas

    Not yet reported Assistance Publique - Hôpitaux de Paris 25 participants Est. completion 2028-09-02 1 site
    Other conditions: Inflammatory Hepatocellular Adenoma
    View official trial listing →
  • Recruiting NCT NCT06573593

    Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

    Second Affiliated Hospital, Zhejiang University, School of Medicine 150 participants Est. completion 2026-12-31 1 site
    Other conditions: Alopecia Areata, Janus Kinase Inhibitors
    View official trial listing →
  • Recruiting NCT NCT06631287

    Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

    Not yet reported Wes Ely 550 participants Est. completion 2027-07-01 17 sites Stand-alone
    Other conditions: Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
    View official trial listing →
  • Recruiting NCT NCT06687551

    JAK Inhibitor Dose TAPering Strategy Study

    Not yet reported University Hospital, Toulouse 308 participants Est. completion 2029-04-01 24 sites Stand-alone
    Other conditions: Rheumatoid Arthritis (RA
    View official trial listing →
  • Recruiting NCT NCT06768840

    Vitiligo, New Treatment and Serum s100B

    Not yet reported, Not yet reported South Valley University 50 participants Est. completion 2025-10 1 site
    Other conditions: Vitiligo, Generalized
    View official trial listing →
  • Recruiting NCT NCT06849908

    Baricitinib in the Treatment of Intestinal Behçet's Syndrome

    Not yet reported Peking Union Medical College Hospital 56 participants Est. completion 2028-06-30 2 sites Stand-alone
    Other conditions: Behcet Syndrome, Intestinal Type
    View official trial listing →
  • Recruiting NCT NCT06923072

    Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 12 participants Est. completion 2030-12-15 1 site Stand-alone
    Other conditions: Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant Atrophic
    View official trial listing →
  • Recruiting NCT NCT06936215

    Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

    Not yet reported Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 24 participants Est. completion 2025-05 1 site Stand-alone
    Other conditions: Diffuse Cutaneous Systemic Sclerosis
    View official trial listing →
  • Recruiting NCT NCT06977035

    Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib

    Not yet reported Sohag University 60 participants Est. completion 2026-06 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT07003997

    JAK Signaling in Depression

    Not yet reported Emory University 100 participants Est. completion 2030-02 1 site Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Recruiting NCT NCT07222137

    A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

    Not yet reported Eli Lilly and Company 150 participants Est. completion 2031-07 113 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Recruiting NCT NCT07222332

    A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

    Not yet reported Eli Lilly and Company 300 participants Est. completion 2028-07 136 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Recruiting NCT NCT07262983

    Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 20 participants Est. completion 2030-10-01 1 site Stand-alone
    Other conditions: Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis
    View official trial listing →
  • Recruiting NCT NCT07279688

    Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

    Not yet reported University Hospital, Brest 140 participants Est. completion 2029-06 23 sites
    Other conditions: Polymyalgia Rheumatica (PMR)
    View official trial listing →
  • Recruiting NCT NCT07406932

    A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

    Not yet reported China-Japan Friendship Hospital 80 participants Est. completion 2027-07-01 1 site Stand-alone
    Other conditions: Antisynthetase Syndrome, Interstitial Lung Disease (ILD)
    View official trial listing →
  • Recruiting NCT NCT07491016

    Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

    Zhejiang Provincial People's Hospital 30 participants Est. completion 2028-03-30 1 site
    Other conditions: Telitacicept, Treatment Compliance, Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT07535645

    Baricitinib for Post-HSCT Persistent Thrombocytopenia

    Not yet reported, Not yet reported Peking University People's Hospital 28 participants Est. completion 2029-09-15 1 site Stand-alone
    Other conditions: Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation
    View official trial listing →
  • Recruiting NCT NCT07554222

    Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

    Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 160 participants Est. completion 2028-12-31 1 site
    Other conditions: Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
    View official trial listing →
  • Completed NCT NCT00902486

    INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

    Not yet reported Incyte Corporation 127 participants Est. completion 2010-07 49 sites
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT01185353

    A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

    Not yet reported Eli Lilly and Company 301 participants Est. completion 2014-03 68 sites Stand-alone
    Other conditions: Arthritis, Rheumatoid
    View official trial listing →
  • Completed NCT NCT01247350

    A Study of LY3009104(Baricitinib) for Healthy Subjects

    Not yet reported Eli Lilly and Company 34 participants Est. completion 2011-04 1 site Stand-alone
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Completed NCT NCT01299285

    Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

    Not yet reported Eli Lilly and Company 6 participants Est. completion 2011-03 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01398475

    A Relative Bioavailability and Food Effect Study of New Formulations

    Not yet reported Eli Lilly and Company 15 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Chronic Inflammatory Disorder, Arthritis, Rheumatoid
    View official trial listing →
  • Completed NCT NCT01469013

    Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy

    Not yet reported Eli Lilly and Company 145 participants Est. completion 2013-12 14 sites Stand-alone
    Other conditions: Arthritis, Rheumatoid
    View official trial listing →
  • Completed NCT NCT01490632

    A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

    Not yet reported Eli Lilly and Company 271 participants Est. completion 2014-08 35 sites Stand-alone
    Other conditions: Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
    View official trial listing →
  • Completed NCT NCT01536951

    A Study of LY3009104 in Healthy Participants

    Not yet reported Eli Lilly and Company 62 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT01683409

    A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

    Not yet reported Eli Lilly and Company 130 participants Est. completion 2014-11 45 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT01710358

    A Study in Moderate to Severe Rheumatoid Arthritis

    Not yet reported Eli Lilly and Company 1307 participants Est. completion 2015-09 213 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT01711359

    A Study in Participants With Moderate to Severe Rheumatoid Arthritis

    Not yet reported Eli Lilly and Company 588 participants Est. completion 2015-08 154 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT01721044

    A Moderate to Severe Rheumatoid Arthritis Study

    Not yet reported Eli Lilly and Company 527 participants Est. completion 2014-09 103 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT01721057

    A Study in Moderate to Severe Rheumatoid Arthritis Participants

    Not yet reported Eli Lilly and Company 684 participants Est. completion 2014-12 147 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Approved For Marketing NCT NCT01724580

    Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

    Eli Lilly and Company 3 sites
    Other conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
    View official trial listing →
  • Completed NCT NCT01859078

    A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

    Not yet reported Eli Lilly and Company 28 participants Est. completion 2013-08 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01870388

    A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

    Not yet reported Eli Lilly and Company 16 participants Est. completion 2013-07 2 sites Stand-alone
    Other conditions: Liver Diseases, Hepatic Insufficiency
    View official trial listing →
  • Completed NCT NCT01885078

    An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

    Not yet reported Eli Lilly and Company 2877 participants Est. completion 2020-11-12 408 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT01896726

    A Study of Baricitinib and Birth Control Pills in Healthy Females

    Not yet reported Eli Lilly and Company 20 participants Est. completion 2013-10 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01910311

    A Study of Baricitinib and Rifampicin in Healthy Participants

    Not yet reported Eli Lilly and Company 18 participants Est. completion 2013-10 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01924299

    A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants

    Not yet reported Eli Lilly and Company 36 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01925144

    A Study of Baricitinib and Omeprazole in Healthy Participants

    Not yet reported Eli Lilly and Company 30 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01937026

    A Study of Baricitinib and Probenecid in Healthy Participants

    Not yet reported Eli Lilly and Company 18 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01960140

    A Study of Baricitinib and Simvastatin in Healthy Participants

    Not yet reported Eli Lilly and Company 40 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01968057

    A Study of Baricitinib and Ciclosporin in Healthy Participants

    Not yet reported Eli Lilly and Company 18 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02263911

    A Study of Baricitinib in Healthy Japanese Participants

    Not yet reported Eli Lilly and Company 16 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT02265705

    A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)

    Not yet reported Eli Lilly and Company 290 participants Est. completion 2017-05 30 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT02340104

    A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants

    Not yet reported Eli Lilly and Company 8 participants Est. completion 2015-02 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02576938

    A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

    Not yet reported Eli Lilly and Company 124 participants Est. completion 2017-03 13 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Completed NCT NCT02708095

    A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

    Not yet reported Eli Lilly and Company 314 participants Est. completion 2017-11-09 84 sites Stand-alone
    Other conditions: Systemic Lupus Erythematosus
    View official trial listing →
  • Completed NCT NCT02758613

    A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

    Not yet reported Eli Lilly and Company 33 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02759731

    Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

    Not yet reported, Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2024-05-30 1 site Stand-alone
    Other conditions: Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
    View official trial listing →
  • Completed NCT NCT03026504

    Baricitinib in Relapsing Giant Cell Arteritis

    Not yet reported Matthew J Koster 15 participants Est. completion 2021-04-12 1 site Stand-alone
    Other conditions: Arteritis, Giant Cell
    View official trial listing →
  • Completed NCT NCT03212638

    A Study of Baricitinib in Healthy Participants

    Not yet reported Eli Lilly and Company 42 participants Est. completion 2017-11-01 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03334396

    A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

    Not yet reported Eli Lilly and Company 660 participants Est. completion 2019-08-16 93 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Completed NCT NCT03334422

    Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

    Not yet reported Eli Lilly and Company 615 participants Est. completion 2018-12-12 80 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Completed NCT NCT03334435

    A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

    Not yet reported Eli Lilly and Company 1645 participants Est. completion 2023-07-12 185 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Completed NCT NCT03428100

    A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

    Not yet reported Eli Lilly and Company 463 participants Est. completion 2023-04-20 103 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Completed NCT NCT03435081

    A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

    Not yet reported Eli Lilly and Company 440 participants Est. completion 2021-08-16 81 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Status unknown NCT NCT03440892

    Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

    Vastra Gotaland Region 2500 participants Est. completion 2025-01 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Terminated NCT NCT03559270

    A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

    Not yet reported Eli Lilly and Company 374 participants Est. completion 2022-06-13 74 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Completed NCT NCT03570749

    A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

    Not yet reported, Not yet reported Eli Lilly and Company 784 participants Est. completion 2025-01-29 75 sites Stand-alone
    Other conditions: Alopecia Areata
    View official trial listing →
  • Terminated NCT NCT03616912

    A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

    Not yet reported Eli Lilly and Company 830 participants Est. completion 2022-03-09 184 sites Stand-alone
    Other conditions: Systemic Lupus Erythematosus
    View official trial listing →
  • Completed NCT NCT03616964

    A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

    Not yet reported Eli Lilly and Company 778 participants Est. completion 2021-10-20 159 sites Stand-alone
    Other conditions: Systemic Lupus Erythematosus
    View official trial listing →
  • Terminated NCT NCT03670069

    Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

    Not yet reported Fred Hutchinson Cancer Center 27 participants Est. completion 2024-05-06 1 site
    Obstructive sleep apnea Other conditions: Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma
    View official trial listing →
  • Status unknown NCT NCT03701789

    Effect of Baricitinib Treatment on Peripheral Bone in RA

    Not yet reported University of Erlangen-Nürnberg Medical School 15 participants Est. completion 2021-10-11 1 site
    Other conditions: Rheumatoid Arthritis, Bone Density, Finger Joints
    View official trial listing →
  • Completed NCT NCT03733301

    A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

    Not yet reported Eli Lilly and Company 329 participants Est. completion 2019-08-22 68 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Terminated NCT NCT03742973

    A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

    Not yet reported Eli Lilly and Company 2 participants Est. completion 2019-09-26 12 sites Stand-alone
    Other conditions: Primary Biliary Cholangitis
    View official trial listing →
  • Status unknown NCT NCT03755466

    Examination of Efficacy and Safety of Baricitinib in RA Patients

    Not yet reported Shinshu University 90 participants Est. completion 2025-11-20 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT03773978

    A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

    Not yet reported Eli Lilly and Company 220 participants Est. completion 2022-01-26 86 sites Stand-alone
    Other conditions: Juvenile Idiopathic Arthritis
    View official trial listing →
  • Terminated NCT NCT03843125

    A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

    Not yet reported Eli Lilly and Company 1147 participants Est. completion 2022-04-01 297 sites Stand-alone
    Other conditions: Systemic Lupus Erythematosus
    View official trial listing →
  • Completed NCT NCT03899259

    A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

    Not yet reported Eli Lilly and Company 606 participants Est. completion 2024-11-19 96 sites Stand-alone
    Other conditions: Alopecia Areata
    View official trial listing →
  • Completed NCT NCT03915964

    A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

    Not yet reported Eli Lilly and Company 2659 participants Est. completion 2025-05-28 261 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT03921554

    JAK Inhibitor Treatment in AGS

    Not yet reported Adeline Vanderver, MD 54 participants Est. completion 2024-03-25 1 site Stand-alone
    Other conditions: Aicardi Goutieres Syndrome
    View official trial listing →
  • Completed NCT NCT03945760

    Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

    Not yet reported Wright State Physicians 23 participants Est. completion 2023-10-16 1 site Stand-alone
    Other conditions: Allergic Contact Dermatitis
    View official trial listing →
  • Completed NCT NCT03952559

    A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

    Not yet reported Eli Lilly and Company 516 participants Est. completion 2026-05-22 78 sites Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Completed NCT NCT04027101

    BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica

    Not yet reported University Hospital, Brest 34 participants Est. completion 2023-08-30 8 sites Stand-alone
    Other conditions: Polymyalgia Rheumatic (PMR)
    View official trial listing →
  • Terminated NCT NCT04084223

    JAKPOT (JAK Inhibitors and Predictors of Outcome in RheumaToid Arthritis)

    Not yet reported University Hospital, Montpellier 51 participants Est. completion 2024-09-24 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT04086745

    A Study of Baricitinib in Participants With Rheumatoid Arthritis

    Not yet reported Eli Lilly and Company 1050 participants Est. completion 2025-05-19 119 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Active, not recruiting NCT NCT04088396

    A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

    Not yet reported Eli Lilly and Company 58 participants Est. completion 2026-10 55 sites Stand-alone
    Other conditions: Systemic Juvenile Idiopathic Arthritis
    View official trial listing →
  • Active, not recruiting NCT NCT04088409

    A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

    Not yet reported Eli Lilly and Company 30 participants Est. completion 2028-07 20 sites Stand-alone
    Other conditions: Uveitis
    View official trial listing →
  • Completed NCT NCT04131738

    Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

    Not yet reported Washington University School of Medicine 26 participants Est. completion 2022-08-17 1 site Stand-alone
    Other conditions: Graft-versus-host-disease, Graft Vs Host Disease
    View official trial listing →
  • Completed NCT NCT04208464

    JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

    Not yet reported University of Manchester 15 participants Est. completion 2023-09-25 1 site Stand-alone
    Other conditions: Idiopathic Inflammatory Myopathies
    View official trial listing →
  • Status unknown NCT NCT04320277

    Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

    Not yet reported, Not yet reported Hospital of Prato 200 participants Est. completion 2020-07-30 1 site Stand-alone
    Other conditions: Pharmacological Action
    View official trial listing →
  • Status unknown NCT NCT04321993

    Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

    Not yet reported Lisa Barrett 363 participants Est. completion 2024-04 1 site Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Withdrawn NCT NCT04340232

    Safety and Efficacy of Baricitinib for COVID-19

    Not yet reported, Not yet reported University of Colorado, Denver Est. completion 2021-10 1 site Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Status unknown NCT NCT04346147

    Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

    Not yet reported Hospital Universitario de Fuenlabrada 168 participants Est. completion 2021-09 1 site Stand-alone
    Other conditions: COVID-19 Pneumonia
    View official trial listing →
  • Completed NCT NCT04358614

    Baricitinib Therapy in COVID-19

    Not yet reported, Not yet reported Fabrizio Cantini 12 participants Est. completion 2020-04-07 1 site
    Other conditions: COVID, Pneumonia
    View official trial listing →
  • Completed NCT NCT04362943

    Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults

    Complejo Hospitalario Universitario de Albacete 576 participants Est. completion 2021-04-15 1 site
    Other conditions: COVID-19
    View official trial listing →
  • Terminated NCT NCT04373044

    Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

    Not yet reported University of Southern California 6 participants Est. completion 2021-05-12 2 sites Stand-alone
    Other conditions: Symptomatic COVID-19 Infection Laboratory-Confirmed
    View official trial listing →
  • Status unknown NCT NCT04378621

    Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients

    Not yet reported Vastra Gotaland Region 212 participants Est. completion 2025-09-01 1 site
    Other conditions: Rheumatoid Arthritis, Pain, Fatigue, Cognitive Decline, Depression, Brain Diseases, Hand Rheumatism
    View official trial listing →
  • Status unknown NCT NCT04390464

    mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 1167 participants Est. completion 2022-05-01 1 site Stand-alone
    Other conditions: COVID19
    View official trial listing →
  • Status unknown NCT NCT04393051

    Baricitinib Compared to Standard Therapy in Patients With COVID-19

    Not yet reported Azienda Ospedaliero, Universitaria Pisana 126 participants Est. completion 2020-07-30 1 site Stand-alone
    Other conditions: Covid-19, SARS-CoV 2, SARS Pneumonia
    View official trial listing →
  • Status unknown NCT NCT04399798

    Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial

    Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 13 participants Est. completion 2020-11-15 Stand-alone
    Other conditions: Corona Virus Infection
    View official trial listing →
  • Completed NCT NCT04401579

    Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 1033 participants Est. completion 2020-07-31 71 sites Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Completed NCT NCT04421027

    A Study of Baricitinib (LY3009104) in Participants With COVID-19

    Not yet reported Eli Lilly and Company 1525 participants Est. completion 2021-06-10 96 sites Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Status unknown NCT NCT04449224

    Comparative Effectiveness of Targeted Therapy in RA Patients

    Hanyang University 506 participants Est. completion 2024-08-19 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Terminated NCT NCT04517253

    A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

    Not yet reported, Not yet reported Eli Lilly and Company 10 participants Est. completion 2024-11-28 5 sites Stand-alone
    Other conditions: Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
    View official trial listing →
  • Completed NCT NCT04640168

    Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 1010 participants Est. completion 2021-06-18 72 sites Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Status unknown NCT NCT04693026

    Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

    Not yet reported M Abdur Rahim Medical College and Hospital 150 participants Est. completion 2021-03-05 1 site Stand-alone
    Other conditions: Covid19, Covid-19 ARDS
    View official trial listing →
  • Completed NCT NCT04774224

    Baricitinib in New-onset Type 1 Diabetes

    Not yet reported St Vincent's Institute of Medical Research 91 participants Est. completion 2024-05-06 4 sites
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT04822584

    Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

    Not yet reported University Hospital, Bordeaux 49 participants Est. completion 2023-04-26 4 sites Stand-alone
    Other conditions: Vitiligo
    View official trial listing →
  • Status unknown NCT NCT04832880

    Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)

    Not yet reported ASST Fatebenefratelli Sacco 4000 participants Est. completion 2022-12 21 sites Stand-alone
    Other conditions: Covid19
    View official trial listing →
  • Active, not recruiting NCT NCT04870203

    Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

    Not yet reported University Hospital, Bordeaux 160 participants Est. completion 2027-03 36 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT04890626

    Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19

    Not yet reported Instituto de Investigación Hospital Universitario La Paz 356 participants Est. completion 2023-07-17 1 site
    Other conditions: SARS-CoV-2 Infection
    View official trial listing →
  • Terminated NCT NCT04891133

    EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

    Not yet reported, Not yet reported Oslo University Hospital 290 participants Est. completion 2023-01-23 92 sites Stand-alone
    Other conditions: COVID-19, Emerging Infectious Disease
    View official trial listing →
  • Completed NCT NCT04901325

    Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

    Not yet reported Oregon Health and Science University 5 participants Est. completion 2025-05-07 1 site Stand-alone
    Other conditions: Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
    View official trial listing →
  • Completed NCT NCT04916756

    A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients

    Not yet reported, Not yet reported Peking Union Medical College Hospital 11 participants Est. completion 2021-03-25 1 site Stand-alone
    Other conditions: Sjogren's Syndrome
    View official trial listing →
  • Withdrawn NCT NCT04970719

    Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

    Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders Est. completion 2021-12 7 sites Stand-alone
    Other conditions: COVID-19 Pneumonia
    View official trial listing →
  • Completed NCT NCT05006768

    Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)

    Not yet reported Genuine Research Center, Egypt 30 participants Est. completion 2021-06-24 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05016297

    Efficacy and Safety of Baricitinib in Sjogren's Syndrome

    Not yet reported Peking Union Medical College Hospital 87 participants Est. completion 2024-11-22 1 site Stand-alone
    Other conditions: Sjogren's Syndrome
    View official trial listing →
  • Status unknown NCT NCT05056558

    Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

    Not yet reported Incepta Pharmaceuticals Ltd 480 participants Est. completion 2022-09 1 site Stand-alone
    Other conditions: Covid19
    View official trial listing →
  • Terminated NCT NCT05074420

    A Study of Baricitinib (LY3009104) in Children With COVID-19

    Not yet reported Eli Lilly and Company 6 participants Est. completion 2024-11-04 14 sites Stand-alone
    Other conditions: Covid19, Corona Virus Infection
    View official trial listing →
  • Status unknown NCT NCT05078294

    Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis

    Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 300 participants Est. completion 2024-11-01 7 sites
    Other conditions: Dermatitis, Atopic
    View official trial listing →
  • Completed NCT NCT05080218

    COVID-19 VaccinE Response in Rheumatology Patients

    Not yet reported Jeffrey Curtis 841 participants Est. completion 2024-05-28 8 sites Stand-alone
    Other conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
    View official trial listing →
  • Completed NCT NCT05082714

    Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

    Not yet reported University Hospital of Patras 251 participants Est. completion 2022-06-04 1 site Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Completed NCT NCT05112120

    Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis

    NHS Greater Glasgow and Clyde 13 participants Est. completion 2023-08-03 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT05119452

    Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis

    Not yet reported Medical University of Vienna 85 participants Est. completion 2024-09
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT05187793

    Study of Efficacy of Different Treatment Regimens of Olokizumab

    Not yet reported R-Pharm 198 participants Est. completion 2023-04 5 sites Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Completed NCT NCT05188521

    Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

    Not yet reported Aaron R. Mangold 12 participants Est. completion 2023-05-17 1 site Stand-alone
    Other conditions: Cutaneous Lichen Planus
    View official trial listing →
  • Completed NCT NCT05189106

    Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

    Not yet reported, Not yet reported Massachusetts General Hospital 17 participants Est. completion 2025-06-20 2 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
    View official trial listing →
  • Completed NCT NCT05237388

    Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

    Not yet reported Duke University 8 participants Est. completion 2026-04-03 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Terminated NCT NCT05238896

    BARIcitinib Cognitive Emotional and Neural signaTuRE

    Not yet reported Assistance Publique - Hôpitaux de Paris 5 participants Est. completion 2023-03-31 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Terminated NCT NCT05263505

    Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

    Not yet reported Washington University School of Medicine 2 participants Est. completion 2023-09-11 1 site Stand-alone
    Other conditions: Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
    View official trial listing →
  • Status unknown NCT NCT05279391

    Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

    Not yet reported Democritus University of Thrace 150 participants Est. completion 2023-12-31 1 site
    Other conditions: COVID-19 Severe Respiratory Failure
    View official trial listing →
  • Active, not recruiting NCT NCT05300932

    A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

    Not yet reported Tongji Hospital 60 participants Est. completion 2026-11-12 2 sites Stand-alone
    Other conditions: Systemic Sclerosis
    View official trial listing →
  • Completed NCT NCT05302947

    COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

    Pirogov Russian National Research Medical University 154 participants Est. completion 2021-06-30 2 sites
    Other conditions: COVID-19, Mild to Moderate
    View official trial listing →
  • Withdrawn NCT NCT05361109

    Baricitinib for Cutaneous Dermatomyositis

    Not yet reported University of Washington Est. completion 2023-03-31 1 site Stand-alone
    Other conditions: Dermatomyositis
    View official trial listing →
  • Withdrawn NCT NCT05379322

    The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

    Not yet reported Abu Dhabi Stem Cells Center Est. completion 2023-03-01 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT05400889

    Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

    Not yet reported Peking University People's Hospital 10 participants Est. completion 2023-06-01 1 site Stand-alone
    Other conditions: Idiopathic Inflammatory Myopathies
    View official trial listing →
  • Status unknown NCT NCT05432531

    Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

    Not yet reported Assiut University 60 participants Est. completion 2023-04-01 1 site Stand-alone
    Other conditions: Lupus Nephritis
    View official trial listing →
  • Status unknown NCT NCT05446831

    Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

    Not yet reported Peking University People's Hospital 35 participants Est. completion 2023-12-01 1 site Stand-alone
    Other conditions: ITP, Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT05524311

    Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

    Not yet reported Assistance Publique - Hôpitaux de Paris 16 participants Est. completion 2026-01-02 13 sites Stand-alone
    Other conditions: Juvenile Dermatomyositis
    View official trial listing →
  • Completed NCT NCT05638932

    Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

    Aetion, Inc. 1442 participants Est. completion 2023-09-25 1 site
    Other conditions: COVID-19
    View official trial listing →
  • Not yet recruiting NCT NCT05651880

    Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

    Not yet reported University Hospital, Rouen 33 participants Est. completion 2029-12 1 site Stand-alone
    Other conditions: Active Non-anterior Non-infectious Uveitis
    View official trial listing →
  • Completed NCT NCT05660655

    Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

    Not yet reported Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 94 participants Est. completion 2023-09-30 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT05686746

    Use of Baricitenib to Maintain of Remission

    Not yet reported, Not yet reported Assiut University 80 participants Est. completion 2023-08-01 1 site Stand-alone
    Other conditions: Lupus or SLE, Nephritis
    View official trial listing →
  • Status unknown NCT NCT05696106

    Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID

    Assistance Publique - Hôpitaux de Paris 750000 participants Est. completion 2024-01-15 1 site
    Other conditions: Inflammatory Disease
    View official trial listing →
  • Status unknown NCT NCT05781516

    Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD

    Not yet reported Wen Zhang 74 participants Est. completion 2025-06 1 site Stand-alone
    Other conditions: IgG4-related Disease With Eosinophilia
    View official trial listing →
  • Active, not recruiting NCT NCT05792462

    Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

    Not yet reported Tianjin Medical University General Hospital 11 participants Est. completion 2027-03-01 1 site Stand-alone
    Other conditions: NMO Spectrum Disorder
    View official trial listing →
  • Status unknown NCT NCT05827497

    Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial

    Not yet reported Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 132 participants Est. completion 2024-03-31 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT05852171

    Baricitinib in Idiopathic Granulomatous Mastitis

    Not yet reported First Affiliated Hospital of Zhejiang University 20 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Mastitis Chronic, Idiopathic Granulomatous Mastitis
    View official trial listing →
  • Status unknown NCT NCT05852847

    Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

    Not yet reported Peking University People's Hospital 216 participants Est. completion 2025-05 10 sites Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Withdrawn NCT NCT05858515

    REVERSE-Long COVID-19 With Baricitinib Study

    Not yet reported Vanderbilt University Medical Center Est. completion 2029-12-30 6 sites Stand-alone
    Other conditions: Post-Acute COVID-19 Syndrome
    View official trial listing →
  • Terminated NCT NCT05897372

    Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

    Not yet reported Iain Bressendorff 1 participants Est. completion 2024-09-23 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT05914584

    "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

    Not yet reported, Not yet reported Nantes University Hospital 450 participants Est. completion 2025-12-31 29 sites Stand-alone
    Other conditions: Hospital-acquired Pneumonia
    View official trial listing →
  • Status unknown NCT NCT05932524

    Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia

    Not yet reported Peking University People's Hospital 132 participants Est. completion 2025-06 10 sites Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Status unknown NCT NCT05950542

    Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo

    Assiut University 30 participants Est. completion 2024-12-30
    Other conditions: Vitiligo, Generalized
    View official trial listing →
  • Completed NCT NCT05969730

    Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis

    Not yet reported Mazandaran University of Medical Sciences 40 participants Est. completion 2025-11-14 1 site Stand-alone
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Status unknown NCT NCT06114407

    Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

    Not yet reported Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 184 participants Est. completion 2024-12-30 1 site Stand-alone
    Other conditions: Spondyloarthritis, Axial
    View official trial listing →
  • Active, not recruiting NCT NCT06158113

    Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

    Not yet reported University of North Carolina, Chapel Hill 10 participants Est. completion 2026-09 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Lichen Planus, Oral, Oral Lichen Planus
    View official trial listing →
  • Active, not recruiting NCT NCT06240351

    A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

    Not yet reported University of Alabama at Birmingham 15 participants Est. completion 2027-09-30 1 site Stand-alone
    Other conditions: Frontal Fibrosing Alopecia
    View official trial listing →
  • Status unknown NCT NCT06366932

    Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

    Not yet reported Instituto de Investigación Hospital Universitario La Paz 150 participants Est. completion 2025-09 1 site
    Other conditions: Atopic Dermatitis
    View official trial listing →
  • Not yet recruiting NCT NCT06439615

    Baricitinib for the Lung Injury Following Spontaneous SAH

    Not yet reported Tang-Du Hospital 100 participants Est. completion 2027-06-30 Stand-alone
    Other conditions: Spontaneous Subarachnoid Hemorrhage
    View official trial listing →
  • Active, not recruiting NCT NCT06475820

    Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

    Not yet reported, Not yet reported Federal Research Institute of Pediatric Hematology, Oncology and Immunology 150 participants Est. completion 2027-04-01 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
    View official trial listing →
  • Status unknown NCT NCT06545110

    Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

    Not yet reported South Valley University 120 participants Est. completion 2024-10-30 1 site
    Other conditions: Alopecia Areata
    View official trial listing →
  • Status unknown NCT NCT06548802

    Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury

    Not yet reported, Not yet reported Tianjin Medical University General Hospital 100 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: Pulmonary Injury After Intracerebral Hemorrhage
    View official trial listing →
  • Status unknown NCT NCT06558305

    IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients

    Assiut University 80 participants Est. completion 2025-04
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT06662721

    Baricitinib for Refractory Takayasu Arteritis

    Not yet reported Liu Tian 10 participants Est. completion 2024-06-08 1 site Stand-alone
    Other conditions: Takayasu Arteritis
    View official trial listing →
  • Completed NCT NCT06737705

    Baricitinib for Patients With Intracerebral Hemorrhage

    Not yet reported De-zhi Kang 110 participants Est. completion 2025-08-18 6 sites Stand-alone
    Other conditions: Intracerebral Hemorrhage
    View official trial listing →
  • Not yet recruiting NCT NCT06768294

    Baricitinib in CPPD - the BAPTIST Study

    Not yet reported I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio 32 participants Est. completion 2027-01 1 site
    Other conditions: Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
    View official trial listing →
  • Not yet recruiting NCT NCT06797310

    Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study

    Not yet reported National Taiwan University Hospital 30 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Alopecia Areata
    View official trial listing →
  • Not yet recruiting NCT NCT06868381

    A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

    Not yet reported Stanford University 10 participants Est. completion 2028-12-01 1 site Stand-alone
    Other conditions: Cardiac Sarcoidosis
    View official trial listing →
  • Completed NCT NCT06898372

    Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome

    IRCCS Fondazione Stella Maris 24 participants Est. completion 2024-12-18 1 site
    Other conditions: Aicardi-Goutières Syndrome (AGS)
    View official trial listing →
  • Completed NCT NCT07028385

    Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1

    Not yet reported Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia 30 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: HIV
    View official trial listing →
  • Not yet recruiting NCT NCT07081763

    Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

    Not yet reported ANRS, Emerging Infectious Diseases 191 participants Est. completion 2030-11 Stand-alone
    Other conditions: HIV-1-infection
    View official trial listing →
  • Not yet recruiting NCT NCT07209267

    Baricitinib Curative Repression of HIV-1

    Not yet reported Emory University 35 participants Est. completion 2028-01 2 sites Stand-alone
    Other conditions: HIV Infection, HIV
    View official trial listing →
  • Not yet recruiting NCT NCT07268534

    Biologics in Folliculitis Decalvans : an Adaptative Trial Research

    Not yet reported Assistance Publique - Hôpitaux de Paris 120 participants Est. completion 2030-04-01 Stand-alone
    Other conditions: Folliculitis Decalvans (FD)
    View official trial listing →
  • Not yet recruiting NCT NCT07357649

    Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis

    Not yet reported Tanta University 100 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Not yet recruiting NCT NCT07448363

    Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica

    Caja Costarricense de Seguro Social 50 participants Est. completion 2031-05 1 site
    Other conditions: Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema), Atopic Dermatitis Patients, Atopic Dermatitis / Eczema, Atopic Dermatitis, Unspecified
    View official trial listing →
  • Not yet recruiting NCT NCT07449910

    Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

    Not yet reported, Not yet reported The First Affiliated Hospital of University of Science and Technology of China 750 participants Est. completion 2028-01-31 1 site Stand-alone
    Cardiovascular disease Other conditions: Baricitinib
    View official trial listing →
  • Not yet recruiting NCT NCT07543458

    Therapeutics for Moderate and Severe Dengue

    Not yet reported Oxford University Clinical Research Unit, Vietnam 8800 participants Est. completion 2031-07-31 18 sites Stand-alone
    Other conditions: Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever
    View official trial listing →
  • Not yet recruiting NCT NCT07608796

    JAK Signaling in Depression and Cognition in Male Football Players

    Not yet reported Emory University 30 participants Est. completion 2027-10 3 sites Stand-alone
    Other conditions: Depressive Symptoms, Cognitive Symptom
    View official trial listing →
  • Completed NCT NCT07645430

    Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.

    Not yet reported Benha University 20 participants Est. completion 2026-06-09 1 site
    Other conditions: Alopecia Areata
    View official trial listing →
  • Completed NCT NCT07662265

    Tocilizumab in Refractory ASS-ILD

    Hu Yinan 111 participants Est. completion 2025-10-31 1 site
    Other conditions: Antisynthetase Syndrome, Tocilizumab
    View official trial listing →
  • Not yet recruiting NCT NCT07669675

    TPO-RA Plus Baricitinib vs. TPO-RA for ITP

    Not yet reported Peking University People's Hospital 100 participants Est. completion 2028-08-31 Stand-alone
    Other conditions: ITP - Immune Thrombocytopenia
    View official trial listing →
  • Not yet recruiting NCT NCT07779642

    Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure

    Not yet reported University of Colorado, Denver 300 participants Est. completion 2030-09
    Other conditions: ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory Failure
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Baricitinib, LY3009104

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.